# Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

> **NCT01858649** · PHASE2 · COMPLETED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 60 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **PROCEDURE:** Metastases resection
- **DRUG:** Bevacizumab
- **DRUG:** 5 FU
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01858649
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858649, "Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01858649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*